2479306-60-8
Chemical Structure
CDK9-IN-19
- CAS No.: 2479306-60-8
- Formula:C26H22F2N4O5
- Molecular Weight:508.47
IUPAC Name: 3-acetyl-7-((5-fluoro-4-(4-fluoro-2-methoxyphenyl)pyrimidin-2-yl)amino)-4-morpholino-2H-chromen-2-one
InChIKey: RDOKVGWGKMHBMG-UHFFFAOYSA-N
SMILES: O=C1C(C(C)=O)=C(N2CCOCC2)C3=C(O1)C=C(NC4=NC=C(F)C(C5=CC=C(F)C=C5OC)=N4)C=C3
Biological Activity: CDK9-IN-19 is a highly potent and selective CDK9 inhibitor with an IC50 value of 2.0 nM. CDK9-IN-19 has excellent cellular antiproliferative activity, moderate pharmacokinetic property and low hERG inhibition. CDK9-IN-19 significantly induces tumour growth inhibition in an MV4-11 xenograft mice model. CDK9-IN-19 can be used for researching acute myeloid leukaemia (AML)[1].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
CDK9-IN-19 | CDK9-IN-19 is a highly potent and selective CDK9 inhibitor with an IC50 value of 2.0 nM. CDK9-IN-19 has excellent cellular antiproliferative activity, moderate pharmacokinetic property and low hERG inhibition. CDK9-IN-19 significantly induces tumour growth inhibition in an MV4-11 xenograft mice model. CDK9-IN-19 can be used for researching acute myeloid leukaemia (AML). | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
